Important Deadline for Mereo BioPharma Investors Facing Significant Losses

Deadline for Mereo BioPharma Group Investors

The Rosen Law Firm, a globally recognized law firm specializing in investor rights, has announced an important update for purchasers of American Depositary Shares (ADS) of Mereo BioPharma Group plc (NASDAQ: MREO). Investors who bought Mereo ADSs during the class period running from June 5, 2023, to December 26, 2025, and have incurred losses of over $100,000 are urged to take action ahead of the approaching deadline of April 6, 2026, to potentially lead a securities fraud lawsuit against the company.

What Investors Need to Know

Investors affected by the alleged misconduct have the opportunity to recover losses without incurring any out-of-pocket expenses through a contingency fee arrangement. According to the law firm, those interested in participating can submit relevant information via the Rosen Law Firm's dedicated website or contact Phillip Kim, Esq., directly via phone or email.

Joining the class action is critical for investors seeking to hold the company accountable for the significant losses suffered. Rosen Law Firm emphasizes that potential lead plaintiffs must file their motion with the court by the April deadline to take on an active role in the litigation.

Background on the Allegations

The lawsuit alleges that Mereo BioPharma misled investors regarding the expected outcomes of their Phase 3 clinical trials, specifically the Orbit and COSMIC studies for setrusumab, aimed at treating Osteogenesis Imperfecta (OI). The false optimism communicated to investors concerning the drug's efficacy—specifically its expected capability to reduce annualized fracture rates in patients—was not supported by the actual results of the trials, which failed to meet primary endpoints.

As reported in the allegations, the company provided misleading statements while omitting crucial details about the trials, leading to investors purchasing shares at inflated prices. Once the truth about the drug's efficacy was revealed, significant financial damages were incurred by the investors.

Why Choose Rosen Law Firm?

Rosen Law Firm stands out due to its proven track record in the field of securities class actions, consistently being ranked among the top firms handling such cases. The firm earned notable recognition in 2017 for achieving the largest securities class action settlement involving a Chinese company and has recovered hundreds of millions of dollars for investors in previous litigation. They have been recognized by ISS Securities Class Action Services for several years, highlighting their reputation for excellence in handling investor rights cases.

Next Steps for Investors

Interested investors who fall within the eligibility criteria are encouraged to act quickly. Detailed instructions for joining the class action can be found at Rosen Law Firm's website. Alternatively, they can directly reach out to Phillip Kim for personalized assistance regarding their potential claims.

It is important for investors to understand that until a class has been certified by the court, they are not represented unless they retain counsel. They also have the option to remain absent from the class and may still benefit from any potential recovery without needing to be a lead plaintiff.

Stay Informed

For ongoing updates and further information, stakeholders are encouraged to follow the Rosen Law Firm on various social media platforms, including LinkedIn, Twitter, and Facebook. Amidst the complexities of securities fraud, it is crucial for all affected investors to seek advice from experienced legal counsel in order to ensure their rights and recovery efforts are adequately represented.

For more information or questions, please contact:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll-Free: (866) 767-3653
Email: [email protected]
Website: www.rosenlegal.com